Same Indication

Nivolumab vs Trimethoprim

Nivolumab vs Trimethoprim: Overview

This comparison examines the pharmacological differences between Nivolumab and Trimethoprim.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Trimethoprim: Dihydrofolate reductase inhibitor (bacterial selective).

Pharmacokinetics

Half-life: Nivolumab — 27 days; Trimethoprim — 8-10 hours.

Chemical Properties

Molecular Formula: Trimethoprim — C14H18N4O3.

Molecular Weight: Trimethoprim — 290.3180 g/mol.

Type: Nivolumab — Antibody; Trimethoprim — Small molecule.